Lauri Ellen Markowitz

Lauri Ellen Markowitz's AcademicInfluence.com Rankings

Medical

#1518

World Rank

#1865

Historical Rank

Public Health

#202

World Rank

#210

Historical Rank

Epidemiology

#223

World Rank

#238

Historical Rank

medical Degrees

Lauri Ellen Markowitz

Philosophy

#4710

World Rank

#7326

Historical Rank

Logic

#2114

World Rank

#3032

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Lauri Ellen Markowitz's Degrees

Doctorate Medicine University of California, San Francisco
Masters Public Health University of California, Berkeley

Why Is Lauri Ellen Markowitz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lauri Ellen Markowitz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). (2007) (2423)
Prevalence of HPV infection among females in the United States. (2007) (1520)
Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels (2013) (1066)
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. (2006) (970)
Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices (2015) (920)
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2019 (2020) (828)
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). (2014) (799)
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (2006) (643)
Human Papillomavirus-Associated Cancers - United States, 2008-2012. (2016) (634)
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014 (2015) (629)
Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. (2016) (614)
Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. (2016) (602)
Prevalence of HPV infection among men: A systematic review of the literature. (2006) (591)
The Prevalence of Bacterial Vaginosis in the United States, 2001–2004; Associations With Symptoms, Sexual Behaviors, and Reproductive Health (2007) (586)
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017 (2018) (580)
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis (2015) (571)
Measles antibody: reevaluation of protective titers. (1990) (564)
Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. (2013) (550)
Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States (2014) (538)
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. (2009) (480)
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis (2019) (465)
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices (2019) (455)
Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections--2002. (2002) (454)
The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. (2007) (447)
Prevalence of Sexually Transmitted Infections Among Female Adolescents Aged 14 to 19 in the United States (2009) (428)
Surveillance of Vaccination Coverage among Adult Populations — United States, 2015 (2017) (403)
Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. (2011) (398)
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2016 (2017) (373)
Human papillomavirus and HPV vaccines: a review. (2007) (366)
O04.4 Seroprevalence of Herpes Simplex Virus Types 1 and 2 United States, 1999–2010 (2013) (357)
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 (2021) (342)
National, state, and local area vaccination coverage among adolescents aged 13-17 years--United States, 2008. (2009) (334)
The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United States (2014) (330)
Prevalence of HPV After Introduction of the Vaccination Program in the United States (2016) (328)
Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015 (2018) (321)
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2015. (2016) (318)
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2018 (2019) (306)
Human papillomavirus vaccine introduction--the first five years. (2012) (296)
First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 (2021) (275)
Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. (2002) (254)
Patient-Delivered Partner Treatment With Azithromycin to Prevent Repeated Chlamydia trachomatis Infection Among Women: A Randomized, Controlled Trial (2003) (251)
Longitudinal Predictors of Human Papillomavirus Vaccine Initiation Among Adolescent Girls in a High-Risk Geographic Area (2011) (249)
Comprehensive control of human papillomavirus infections and related diseases. (2013) (247)
Human Papillomavirus Vaccination Practices: A Survey of US Physicians 18 Months After Licensure (2010) (238)
Duration of live measles vaccine-induced immunity. (1990) (226)
Human Papillomavirus–Attributable Cancers — United States, 2012–2016 (2019) (222)
Human Papillomavirus Vaccination Series Initiation and Completion, 2008–2009 (2011) (215)
Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. (2005) (209)
Noninfluenza Vaccination Coverage Among Adults — United States, 2012 (2014) (209)
Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. (2009) (206)
The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. (2007) (205)
Surveillance of Vaccination Coverage Among Adult Populations —United States, 2018 (2021) (204)
Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. (2009) (203)
The cost-effectiveness of male HPV vaccination in the United States. (2011) (201)
Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. (2012) (194)
Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. (2010) (190)
Vaccination Coverage Among Adults, Excluding Influenza Vaccination — United States, 2013 (2015) (186)
A National Survey of Pediatrician Knowledge and Attitudes Regarding Human Papillomavirus Vaccination (2006) (185)
Acceptability of human papillomavirus vaccine for males: a review of the literature. (2010) (185)
Present status of human papillomavirus vaccine development and implementation. (2015) (181)
Human Papillomavirus Prevalence and Type Distribution in Male Anogenital Sites and Semen (2007) (178)
Prevalence of HPV in Adults Aged 18-69: United States, 2011-2014. (2017) (166)
Nucleic Acid Amplification Tests for Diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis Rectal Infections (2010) (163)
Patterns of transmission in measles outbreaks in the United States, 1985-1986. (1989) (161)
Human papillomavirus vaccine and sexual behavior among adolescent and young women. (2012) (155)
Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. (2002) (155)
Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. (2004) (152)
Use of a 2‐Dose Schedule for Human Papillomavirus Vaccination—Updated Recommendations of the Advisory Committee on Immunization Practices (2017) (144)
Genital Warts Among 18- to 59-Year-Olds in the United States, National Health and Nutrition Examination Survey, 1999–2004 (2008) (144)
Cost-effectiveness of Human Papillomavirus Vaccination in the United States (2008) (142)
Prevalence of Circumcision and Herpes Simplex Virus Type 2 Infection in Men in the United States: The National Health and Nutrition Examination Survey (NHANES), 1999–2004 (2007) (141)
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 (2021) (140)
Trends in Pelvic Inflammatory Disease Hospital Discharges and Ambulatory Visits, United States, 1985–2001 (2005) (140)
Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal (1995) (140)
Risk factors for anogenital human papillomavirus infection in men. (2007) (137)
Successes and failures in measles control. (1994) (135)
Comprehensive control of human papillomavirus infections and related diseases. (2013) (134)
Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. (1990) (134)
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2020 (2021) (132)
Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. (2015) (127)
Duration of Untreated Genital Infections With Chlamydia trachomatis: A Review of the Literature (2000) (125)
National Seroprevalence and Trends in Herpes Simplex Virus Type 1 in the United States, 1976–1994 (2004) (123)
Prevalence of Human Papillomavirus Among Females After Vaccine Introduction—National Health and Nutrition Examination Survey, United States, 2003–2014 (2017) (120)
Incidence of herpes simplex virus type 2 infection in the United States. (2001) (119)
Nosocomial Legionnaires' disease. Epidemiologic demonstration of cooling towers as a source. (1985) (119)
Sexually Transmitted Infections Among US Women and Men: Prevalence and Incidence Estimates, 2018. (2021) (118)
Human papillomavirus vaccine initiation among adolescent girls in high-risk communities. (2011) (117)
Legionella prosthetic-valve endocarditis. (1988) (116)
Men Who Have Sex With Men in the United States: Demographic and Behavioral Characteristics and Prevalence of HIV and HSV-2 Infection: Results from National Health and Nutrition Examination Survey 2001–2006 (2010) (115)
Nucleic Acid Amplification Tests for Diagnosis of Neisseria gonorrhoeae Oropharyngeal Infections (2009) (115)
CDC Grand Rounds: Reducing the Burden of HPV-Associated Cancer and Disease (2014) (114)
Women Who Have Sex With Women in The United States: Prevalence, Sexual Behavior and Prevalence of Herpes Simplex Virus Type 2 Infection—Results From National Health and Nutrition Examination Survey 2001–2006 (2010) (113)
Ten Years of Human Papillomavirus Vaccination in the United States. (2018) (112)
Syncope after vaccination--United States, January 2005-July 2007. (2008) (110)
Trends and Patterns of Sexual Behaviors Among Adolescents and Adults Aged 14 to 59 Years, United States (2015) (110)
An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease. (1989) (108)
Measles outbreak among unvaccinated preschool-aged children: opportunities missed by health care providers to administer measles vaccine. (1989) (107)
Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. (1996) (102)
Evaluation of monoclonal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus (1991) (100)
Post-licensure monitoring of HPV vaccine in the United States. (2010) (99)
The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. (1995) (98)
Ocular Syphilis - Eight Jurisdictions, United States, 2014-2015. (2016) (98)
Trichomonas vaginalis Prevalence, Incidence, Risk Factors and Antibiotic-Resistance in an Adolescent Population (2010) (98)
Fatal measles pneumonia without rash in a child with AIDS. (1988) (97)
A Case–Control Study of Syphilis Among Men Who Have Sex With Men in New York City: Association With HIV Infection (2004) (95)
The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. (1996) (94)
Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. (2007) (92)
The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States: implications for dentistry. (2011) (91)
Multiple-Type Human Papillomavirus Infection in Male Anogenital Sites: Prevalence and Associated Factors (2009) (89)
Lyme disease surveillance in the United States, 1983-1986. (1989) (89)
Declining prevalence of HIV‐1 infection in young Thai men (1995) (89)
Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. (1996) (88)
Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. (2012) (84)
Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. (2009) (84)
Suppressive Acyclovir Therapy Reduces HIV Cervicovaginal Shedding in HIV- and HSV-2-Infected Women, Chiang Rai, Thailand (2008) (84)
Primary Care Physicians’ Perspectives About HPV Vaccine (2016) (83)
Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. (2016) (83)
Genital human papillomavirus infection. (2006) (82)
An evaluation of measles revaccination among school-entry-aged children. (1996) (82)
Epidemiology of measles in the United States in 1989 and 1990. (1992) (80)
Appropriate age for measles vaccination in the United States. (1986) (80)
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes (2016) (80)
Persistence of measles antibody after revaccination. (1992) (80)
Molecular subtyping of Treponema pallidum in an Arizona County with increasing syphilis morbidity: use of specimens from ulcers and blood. (2001) (79)
Investigation of Metronidazole Use during Pregnancy and Adverse Birth Outcomes (2012) (79)
A persistent outbreak of measles despite appropriate prevention and control measures. (1987) (78)
Tick-borne tularemia. An outbreak of lymphadenopathy in children. (1985) (78)
Factors associated with human papillomavirus vaccination among young adult women in the United States. (2013) (77)
Transmission of measles in medical settings--United States, 1985-1989. (1991) (77)
The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. (2005) (77)
Comprehensive control of human papillomavirus infections and related diseases. (2013) (77)
Seroprevalence of herpes simplex virus type 1 in children in the United States. (2007) (76)
Prevalence of Chlamydia trachomatis Infection Among Men Screened in 4 U.S. Cities (2005) (74)
Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection (1993) (74)
Population impact of HPV vaccines: summary of early evidence. (2013) (73)
Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. (1998) (72)
Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact? (2011) (71)
Corrigendum to: “Human Papillomavirus Vaccine Introduction – The First Five Years” [Vaccine 30 (Suppl. 5) (2012) F139–F148] (2014) (70)
Vaccination levels and missed opportunities for measles vaccination: a record audit in a public pediatric clinic. (1992) (70)
Sex-specific differences in mortality after high-titre measles immunization in rural Senegal. (1994) (70)
Primary and secondary syphilis among men who have sex with men--New York City, 2001. (2002) (68)
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe (2022) (68)
The Natural History of HIV-1 Infection in Young Thai Men After Seroconversion (2004) (68)
Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007–2012, and Postlicensure Vaccine Safety Monitoring, 2006–2013 — United States (2013) (67)
Prevalence of Genital Human Papillomavirus in Males, United States, 2013–2014 (2017) (66)
Provider perceptions of barriers and facilitators of HPV vaccination in a high-risk community. (2012) (66)
Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. (2004) (66)
Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008. (2011) (66)
Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. (2008) (65)
Willingness to participate in HIV-1 vaccine trials among young Thai men (2000) (65)
Amplification of the DNA polymerase I gene of Treponema pallidum from whole blood of persons with syphilis. (2001) (65)
Control of epidemic group A meningococcal meningitis in Nepal. (1987) (63)
Delay and Refusal of Human Papillomavirus Vaccine for Girls, National Immunization Survey–Teen, 2010 (2014) (63)
Increased Susceptibility to Measles in Infants in the United States (1999) (61)
Repeat Chlamydia trachomatis infection in women: analysis through a surveillance case registry in Washington State, 1993-1998. (2000) (61)
Trends in Seroprevalence of Herpes Simplex Virus Type 2 Among Non-Hispanic Blacks and Non-Hispanic Whites Aged 14 to 49 Years—United States, 1988 to 2010 (2013) (61)
Human papillomavirus genotypes in high-grade cervical lesions in the United States. (2012) (60)
Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. (2018) (60)
A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. (2000) (60)
Human Papillomavirus Vaccination (2007) (59)
Prevalence of Circumcision Among Men and Boys Aged 14 to 59 Years in the United States, National Health and Nutrition Examination Surveys 2005–2010 (2013) (59)
Vitamin A levels and mortality among hospitalized measles patients, Kinshasa, Zaire. (1989) (59)
Prevalence of cervical and oral human papillomavirus infections among US women. (2014) (59)
Measles outbreaks in the United States, 1987 through 1990. (1996) (59)
Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014 (2019) (58)
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States (2016) (58)
Reporting efficiency during a measles outbreak in New York City, 1991. (1993) (57)
Nationwide surveillance of HIV-1 prevalence and subtype in young Thai men. (1998) (56)
Comparison of Methods for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae Using Commercially Available Nucleic Acid Amplification Tests and a Liquid Pap Smear Medium (2003) (56)
A measles outbreak at a college with a prematriculation immunization requirement. (1991) (56)
Clinical efficacy of measles vaccine during the 1990 measles epidemic (1991) (56)
Molecular Subtyping of Treponema pallidum from North and South Carolina (2005) (55)
Pediatric emergency room visits: a risk factor for acquiring measles. (1991) (55)
Population‐based trends in high‐grade cervical lesions in the early human papillomavirus vaccine era in the United States (2015) (55)
Use of Home-Obtained Vaginal Swabs to Facilitate Rescreening for Chlamydia trachomatis Infections: Two Randomized Controlled Trials (2011) (53)
Prevalence of Syphilis Seroreactivity in the United States: Data From the National Health and Nutrition Examination Surveys (NHANES) 2001–2004 (2008) (52)
Seroprevalence of human papillomavirus type 16 in children. (2005) (52)
HPV Type Attribution in High-Grade Cervical Lesions: Assessing the Potential Benefits of Vaccines in a Population-Based Evaluation in the United States (2014) (52)
Systematic review of human papillomavirus vaccine coadministration. (2014) (51)
TPrevalence of HPV in Adults Aged 18-69: United States, 2011-2014. (2017) (50)
Individual and geographic disparities in human papillomavirus types 16/18 in high‐grade cervical lesions (2013) (50)
Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women — United States, 2008 and 2016 (2019) (50)
Measles among the Amish: a comparative study of measles severity in primary and secondary cases in households. (1991) (50)
Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls (2016) (50)
Correlation of genetic and serologic approaches to HIV-1 subtyping in Thailand. (1996) (49)
Evaluation of the Determine Rapid Syphilis TP Assay Using Sera (2004) (49)
Acute measles mortality in the United States, 1987-2002. (2004) (48)
A school-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. (1990) (47)
Evolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians. (2013) (46)
The geographic distribution of measles in the United States, 1980 through 1989. (1992) (46)
The Geographic Distribution of Lyme Disease in the United States (1988) (45)
Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men-United States, 2012-2014. (2016) (45)
HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011. (2014) (44)
Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016. (2018) (44)
Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006. (2016) (44)
Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. (2009) (44)
High attack rates and case fatality during a measles outbreak in groups with religious exemption to vaccination. (1993) (44)
Measles in hospitalized African children with human immunodeficiency virus. (1988) (44)
Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. (2011) (44)
HPV vaccination of boys in primary care practices. (2013) (43)
Response of human immunodeficiency virus-infected adults to measles-rubella vaccination. (1993) (43)
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021 (2022) (43)
Developments in the screening for Chlamydia trachomatis: a review. (2003) (43)
Sexual behavior of young men in Thailand: regional differences and evidence of behavior change. (1998) (43)
Increasing Human Papillomavirus Vaccine Coverage Among Men Who Have Sex With Men—National HIV Behavioral Surveillance, United States, 2014 (2017) (42)
Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008–2015 (2018) (42)
Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. (2016) (42)
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. (2018) (41)
A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. (1992) (41)
Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines. (2011) (41)
The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model (2016) (41)
Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine — United States, 2003–2018 (2021) (40)
Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States (2019) (40)
The Emergence of Neisseria gonorrhoeae With Decreased Susceptibility to Azithromycin in Kansas City, Missouri, 1999 to 2000 (2004) (40)
Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. (2015) (39)
Molecular Typing of Treponema pallidum in Ocular Syphilis (2016) (39)
Rate and Predictors of Repeat Chlamydia trachomatis Infection Among Men (2008) (39)
Racial and ethnic disparities in human papillomavirus‐associated cancer burden with first‐generation and second‐generation human papillomavirus vaccines (2016) (38)
Measles outbreaks in religious groups exempt from immunization laws. (1988) (38)
The burden of acute respiratory infection due to measles in developing countries and the potential impact of measles vaccine. (1991) (38)
HPV Vaccine Delivery Practices by Primary Care Physicians (2019) (38)
Adverse events following measles-mumps-rubella and measles vaccinations in college students. (1991) (38)
The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions (2012) (38)
Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices (2019) (38)
The 1988-1989 measles epidemic in Hungary: assessment of vaccine failure. (1992) (37)
Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. (1996) (37)
Persons with early syphilis identified through blood or plasma donation screening in the United States. (2002) (37)
The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. (2008) (37)
Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. (1994) (36)
Association of Provider Recommendation and Human Papillomavirus Vaccination Initiation among Male Adolescents Aged 13‐17 Years—United States (2019) (36)
HPV vaccines prophylactic, not therapeutic. (2007) (36)
Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men and Transgender Women in 2 US Cities, 2012–2014 (2017) (36)
HPV 6/11, 16, 18 Seroprevalence in Men in Two US Cities (2009) (35)
Childhood immunization, vaccine-preventable diseases and infection with human immunodeficiency virus. (1988) (35)
Sexually transmitted disease services at US colleges and universities. (2005) (35)
Correlates of HIV-1 seropositivity among young men in Thailand. (1996) (34)
Sexually Transmitted Diseases of Older Persons in Washington State (2001) (34)
Increases in Ocular Syphilis—North Carolina, 2014–2015 (2016) (33)
Evaluation of an early two-dose measles vaccination schedule. (2001) (33)
Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine. (2016) (33)
Serologic screening, mass immunization, and implications for immunization programs. (1991) (31)
Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States. (2011) (31)
Prevalence of Genital Human Papillomavirus Among Sexually Experienced Males and Females Aged 14–59 Years, United States, 2013–2014 (2018) (31)
Child mortality after high-titre measles vaccines in Senegal: the complete data set (1991) (31)
Syphilis Outbreak Among Hispanic Immigrants in Decatur, Alabama: Association With Commercial Sex (2004) (30)
Maternal underestimation of child's sexual experience: suggested implications for HPV vaccine uptake at recommended ages. (2013) (30)
Parent Attitudes about School Requirements for Human Papillomavirus Vaccine in High-Risk Communities of Los Angeles, California (2011) (30)
Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. (2019) (30)
Risk Factors for Sexually Transmitted Diseases in Northern Thai Adolescents: An Audio-Computer-Assisted Self-Interview With Noninvasive Specimen Collection (2003) (30)
HPV Genotypes in High Grade Cervical Lesions and Invasive Cervical Carcinoma as Detected by Two Commercial DNA Assays, North Carolina, 2001–2006 (2012) (29)
Diversity of envelope glycoprotein from human immunodeficiency virus type 1 of recent seroconverters in Thailand. (2000) (29)
Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey. (2019) (29)
A comparison of vaccine efficacy and mortality during routine use of high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in rural Senegal. (1996) (29)
Assessing Neonatal Herpes Reporting in the United States, 2000–2005 (2008) (28)
Human Papillomavirus Vaccination and Age at First Sexual Activity, National Health and Nutrition Examination Survey (2017) (28)
Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. (2019) (28)
Health care use and opportunities for human papillomavirus vaccination among young men who have sex with men. (2013) (27)
Chlamydia Partner Services for Females in California Family Planning Clinics (2011) (27)
Immunogenicity of high-titer Edmonston-Zagreb measles vaccine in human immunodeficiency virus-infected children in Kinshasa, Zaire. (1993) (26)
Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009. (2012) (26)
Monitoring the impact of HPV vaccine in males—Considerations and challenges (2016) (26)
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015 (2020) (26)
Acceptability of Carraguard Vaginal Microbicide Gel among HIV-Infected Women in Chiang Rai, Thailand (2011) (26)
Prevalence of Neisseria gonorrhoeae Among Men Screened for Chlamydia trachomatis in Four United States Cities, 1999–2003 (2006) (25)
Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. (2006) (25)
Population‐attributable fraction of tubal factor infertility associated with chlamydia (2017) (25)
Trends in human papillomavirus (HPV) vaccination initiation among adolescents aged 13–17 by metropolitan statistical area (MSA) status, National Immunization Survey – Teen, 2013 – 2017 (2019) (25)
Seroepidemiology of Human Papillomavirus Type 11 in the United States: Results From the Third National Health and Nutrition Examination Survey, 1991–1994 (2008) (24)
Sexually Transmitted Diseases During Pregnancy: Screening, Diagnostic, and Treatment Practices Among Prenatal Care Providers in Georgia (2001) (23)
Uptake of human papillomavirus vaccine among adolescent males and females: Immunization Information System sentinel sites, 2009-2012. (2014) (23)
Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the USA, National Health and Nutrition Examination Surveys, 2003–2006 (2014) (23)
Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States (2018) (22)
National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2021 (2022) (22)
Seroprevalence of Herpes Simplex Virus Types 1 and 2 Among Pregnant Women and Sexually Active, Nonpregnant Women in the United States (2018) (22)
A comparative study of the impact of HIV infection on natural killer cell number and function in Thais and North Americans. (2000) (21)
Update--the United States measles epidemic, 1989-1990. (1992) (21)
Immunization of young infants with Edmonston-Zagreb measles vaccine. (1987) (21)
Transgender Women Have Higher Human Papillomavirus Prevalence Than Men Who Have Sex With Men-Two U.S. Cities, 2012-2014. (2019) (20)
Human Papillomavirus Vaccination History Among Women With Precancerous Cervical Lesions: Disparities and Barriers (2012) (20)
A Prospective Study of the Psychosocial Impact of a Positive Chlamydia trachomatis Laboratory Test (2011) (20)
Acceptability of school requirements for human papillomavirus vaccine (2011) (20)
Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012 (2015) (20)
A cost-effectiveness analysis of measles outbreak control strategies. (1987) (19)
A public health approach to adverse outcomes of pregnancy associated with bacterial vaginosis (1999) (19)
Adolescent vaccination: recommendations from the National Vaccine Advisory Committee. (2009) (19)
Worldwide measles prevention. (1994) (19)
Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States (2019) (19)
No evidence of long-term immunosuppression after high-titer Edmonstron-Zagreb measles vaccination in Senegal. (1995) (18)
Screening of males for Chlamydia trachomatis and Neisseria gonorrhoeae infections at STD clinics in three US cities — Indianapolis, New Orleans, Seattle (2004) (18)
Incidence of Genital Warts in Adolescents and Young Adults in an Integrated Health Care Delivery System in the United States Before Human Papillomavirus Vaccine Recommendations (2013) (17)
Incidence of Neonatal Herpes Simplex Virus Infections in Two Managed Care Organizations: Implications for Surveillance (2008) (17)
A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. (2000) (17)
Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States. (2018) (17)
HIV genital shedding and safety of Carraguard use by HIV-infected women: a crossover trial in Thailand (2010) (17)
Measles control in Kinshasa, Zaire improved with high coverage and use of medium titre Edmonston Zagreb vaccine at age 6 months. (1994) (17)
Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men—United States, 2016–2018 (2020) (16)
Contact-Tracing Outcomes Among Male Syphilis Patients in Fulton County, Georgia, 2003 (2007) (16)
Expedited Partner Therapy in Federally Qualified Health Centers—New York City, 2012 (2013) (16)
Concordance Between Anal and Oral Human Papillomavirus Infections Among Young Men Who have Sex With Men (2017) (16)
Human papillomavirus vaccination coverage among men who have sex with men-National HIV Behavioral Surveillance, United States, 2017. (2020) (15)
“Testing-Only” Visits: An Assessment of Missed Diagnoses in Clients Attending Sexually Transmitted Disease Clinics (2013) (15)
New, and Some Not-so-New, Vaccines for Adolescents and Diseases They Prevent (2008) (15)
Pre-Treatment Syphilis Titers: Distribution and Evaluation of Their Use to Distinguish Early From Late Latent Syphilis and to Prioritize Contact Investigations (2009) (15)
Five year follow-up of morbidity and mortality among recipients of high-titre measles vaccines in Senegal. (1996) (15)
The science of vaccine safety: Summary of meeting at Wellcome Trust. (2020) (15)
Immunizations in college health: the remaining tasks. (1987) (15)
Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand. (1999) (15)
Mortality and morbidity after high titre measles vaccine in Mexico (1992) (14)
Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. (2013) (14)
HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies. (2001) (14)
Minor consent and delivery of adolescent vaccines. (2010) (14)
The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States. (2014) (14)
Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018 (2022) (13)
Measles hospitalizations, United States, 1977-84: comparison with national surveillance data. (1987) (13)
Genotype-Specific Concordance of Chlamydia trachomatis Genital Infection Within Heterosexual Partnerships (2016) (13)
Two vs Three Doses of Human Papillomavirus Vaccine: New Policy for the Second Decade of the Vaccination Program. (2016) (13)
Risk factors associated with severe measles in Puerto Rico. (1992) (13)
CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide (2017) (13)
Availability of human papillomavirus vaccine at medical practices in an area with elevated rates of cervical cancer. (2009) (13)
Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model. (2020) (12)
Evaluation of Syphilis Reactor Grids: Optimizing Impact (2003) (12)
Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007-2014. (2018) (12)
International measles importations United States, 1980-1985. (1988) (12)
HPV vaccine implementation in STD clinics--STD Surveillance Network. (2012) (11)
Evaluation of genital self-sampling methods for HPV detection in males. (2013) (11)
US Primary Care Physicians’ Viewpoints on HPV Vaccination for Adults 27 to 45 Years (2021) (11)
Significant Declines in Juvenile Onset Recurrent Respiratory Papillomatosis following HPV Vaccine Introduction in the United States. (2021) (11)
Comprehensive control of human papillomavirus infections and related diseases. (2013) (11)
Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. (2015) (11)
Estimated prevalence and incidence of disease-associated HPV types among 15-59-year-olds in the United States. (2021) (11)
Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact (2013) (11)
Effect of specimen order on Chlamydia trachomatis and Neisseria gonorrhoeae test performance and adequacy of Papanicolaou smear. (2006) (10)
Evaluation of Syracuse Healthy Start’s Program for Abnormal Flora Management to Reduce Preterm Birth Among Pregnant Women (2011) (10)
DTH responsiveness of HIV-infected Thai adults. (2000) (10)
The cost-effectiveness of human papillomavirus vaccine catch-up programs for women. (2015) (10)
Human papillomavirus vaccination coverage using two-dose or three-dose schedule criteria. (2017) (10)
Toxic shock syndrome. Evaluation of national surveillance data using a hospital discharge survey. (1987) (10)
HIV viral load in Thai men and women with subtype E infections. (2001) (10)
Manual for the surveillance of vaccine-preventable diseases. Chapter 5: Human Papillomavirus (HPV) (2011) (10)
Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18 (2020) (10)
Can clinical tests help monitor human papillomavirus vaccine impact? (2013) (10)
Effectiveness of 1, 2, AND 3 Human Papillomavirus Vaccine doses against HPV-16/18 positive High-grade Cervical Lesions. (2019) (9)
Primary and secondary prevention of cervical cancer--opportunities and challenges. (2009) (9)
Uptake of 2009 H1N1 vaccine among adolescent females (2011) (9)
Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003–2010✩ (2015) (9)
Increase in Sexual Risk Behavior and Prevalence of Chlamydia trachomatis Among Adolescents in Northern Thailand (2008) (9)
Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era. (2018) (9)
Invasive and in situ cervical cancer reported to the vaccine adverse event reporting system (VAERS). (2010) (8)
Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination (2019) (8)
The Syphilis Reactor Grid:: Help or Hindrance for Syphilis Surveillance? (2003) (8)
Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States (2022) (8)
Early Syphilis Among Men Who Have Sex with Men in the US Pacific Northwest, 2008-2013: Clinical Management and Implications for Prevention. (2016) (8)
Cervical Specimen Order and Performance Measures of Chlamydia trachomatis Diagnostic Testing (2005) (8)
Risk Factors for Oral Human Papillomavirus Infection Among Young Men Who Have Sex With Men-2 Cities, United States, 2012-2014. (2018) (7)
Effectiveness Of Human Papillomavirus (HPV) Vaccination Against Penile Hpv Infection In Men Who Have Sex With Men And Transgender Women. (2021) (7)
Timing of HPV vaccine intervals among United States teens with consideration to the current ACIP schedule and the WHO 2-dose schedule (2016) (7)
Frequency of HIV false positivity from two sequential enzyme immunoassays in 111 639 sera. (1999) (7)
Juvenile-Onset Recurrent Respiratory Papillomatosis in the United States, Epidemiology and HPV Types-2015-2020. (2021) (7)
Disclosure of Sexual Behavior Is Significantly Associated With Receiving a Panel of Health Care Services Recommended for Men Who Have Sex With Men (2018) (7)
Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003–2006 (2016) (7)
Changes in Strength of Recommendation and Perceived Barriers to HPV Vaccination: Longitudinal Analysis of Primary Care Physicians, 2008-2018. (2021) (7)
HIV-1 and herpes simplex virus type-2 genital shedding among co-infected women using self-collected swabs in Chiang Rai, Thailand (2012) (7)
Vaccine effectiveness on DNA prevalence of human papillomavirus infection in anal and oral specimens from men who have sex with men- United States, 2016-2018. (2020) (6)
Seroprevalence of human papillomavirus 6/11/16/18 among self-identified gay/bisexual men who have sex with men, men who have sex with women, and females, United States, 2003-2010. (2018) (6)
HPV genotypes detected in cervical cancers from Alaska Native women, 1980–2007 (2013) (6)
MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) (2010) (6)
The effect of measles-rubella vaccination on lymphocyte populations and subpopulations in HIV-infected and healthy individuals. (1992) (5)
Response to Pendleton et al. regarding reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States. (2016) (5)
The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018. (2021) (5)
Sexual Positioning Practices and Anal Human Papillomavirus Infection Among Young Men Who Have Sex with Men and Transgender Women—Chicago, Illinois, 2016–2018 (2021) (5)
Serologic response to measles vaccination among ill children (1992) (5)
Measuring Adolescent Human Papillomavirus Vaccine Coverage: A Match of Sexually Transmitted Disease Clinic and Immunization Registry Data. (2016) (5)
Challenges in Congenital Syphilis Surveillance: How Are Congenital Syphilis Investigations Classified? (2013) (5)
16 – Human papillomavirus vaccines (2013) (5)
Human papilloma virions in the laboratory. (2014) (5)
Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule (2021) (5)
Cervical Cancer Screening and Prevention in 78 Sexually Transmitted Disease Clinics—United States, 2014–2015 (2017) (4)
A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand (2022) (4)
Chapter 5: Human Papillomavirus (2008) (4)
Human Papillomavirus Vaccination Trends Among Adolescents: 2015 to 2020. (2022) (4)
Missed opportunities for preventing congenital syphilis infection. (2013) (4)
Review of the current published evidence on single-dose HPV vaccination 2nd Edition (2019) (4)
Expanded age range for 9-valent HPV vaccine : background for policy considerations (2018) (4)
Increasing human papillomavirus vaccination at the recommended age. (2019) (4)
Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding (2016) (4)
Examining self and partners for syphilis among men who have sex with men: five US cities, 2009-2011 (2012) (4)
Risk factors for oral HPV infection among young men who have sex with men - 2 cities, United States, 2012-2014. (2018) (4)
Sensitivity of Self-Reported Human Papillomavirus Vaccination History Among 18- to 26-Year-Old Men Who Have Sex With Men: Seattle, WA, 2016 to 2018 (2021) (4)
2-dose human papillomavirus (HPV) vaccination schedules (2014) (4)
2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017 (2018) (3)
Monitoring HPV vaccine impact: early results and ongoing challenges. (2012) (3)
O16.4 The estimated impact and cost-effectiveness of nonavalent hpv vaccination in the united states (2015) (3)
The Prevalence of Trichomonas Vaginalis in the United States, 2001–2002 (2006) (3)
Manual for the surveillance of vaccine-preventable diseases. Chapter 7: Measles (2013) (3)
HPV type‐specific trends in cervical precancers in the United States, 2008 to 2016 (2022) (3)
30 – Human Papillomavirus Vaccines (2018) (3)
National and State-Specific Estimates of Settings of Receiving Human Papillomavirus Vaccination Among Adolescents in the United States. (2021) (3)
HPV vaccine - update (2012) (3)
The experience with measles in the United States (1993) (3)
HPV prevalence among young adult women living with and without HIV in Botswana for future HPV vaccine impact monitoring (2022) (3)
Would Young Women Attending Sexually Transmitted Disease Clinics Benefit From Human Papillomavirus Vaccination? An Assessment of Human Papillomavirus DNA and Seropositivity From Human Papillomavirus Sentinel Surveillance, 2003–2005 (2014) (3)
Manual for the surveillance of vaccine-preventable diseases. Chapter 6: Influenza (2011) (3)
Increases in Human Papillomavirus Testing Preceding Diagnosis of Cervical Precancer in 5 US States, 2008–2016 (2021) (2)
Primary care physician support for harmonizing HPV vaccination recommendations across genders - United States, 2018. (2020) (2)
Disparities in human papillomavirus vaccination coverage in the United States, National Health and Nutrition Examination Survey, January 2017-March 2020. (2022) (2)
Safety Monitoring of mRNA Vaccines Administered During the Initial 6 Months of the U.S. COVID-19 Vaccination Program: Reports to Vaccine Adverse Events Reporting System (VAERS) and v-safe (2021) (2)
Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination. (2019) (2)
Transmission and Severity of Measles Acquired in Medical Settings-Reply (1986) (2)
Serologic Assays for the Diagnosis of Herpes Virus 1 (HSV-1) Herpes Virus 2 (HSV-2): Test Characteristics of FDA Approved Type-Specific Assays in an Ethnically, Racially, and Economically Diverse Patient Population (2015) (2)
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. (2011) (2)
Human papillomavirus vaccination coverage among young, gay, bisexual, and other men who have sex with men and transgender women — 3 U.S. cities, 2016–2018 (2021) (2)
An Evaluation of Dose-related HPV Vaccine Effectiveness Using Central Registries in Michigan. (2021) (2)
TICK-BORNE TULAREMIA: AN OUTBREAK OF LYMPHADENOPATHY IN CHILDREN (1986) (2)
Sex differences in measles fatality and Edmonston-Zagreb measles vaccine (1994) (2)
Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs. (2022) (2)
Human Papillomavirus Vaccines. (2021) (2)
16. The Role of State Human Papillomavirus (HPV) Vaccine Financing and Legislative Policies on HPV Vaccination Rates Among Girls, 13-17 Years, National Immunization Survey-Teen, 2008 and 2010 (2013) (1)
Human Papillomavirus and HPV Vaccines: A review/Virus Du Papillome Humain et Vaccins Anti-VPH: bilan/Papilomavirus Humanos Y Vacunas Anti-PVH: Revision (2007) (1)
Prevalence of human papillomavirus among females older than recommended age for vaccination by birth cohort, United States 2003‒2016. (2021) (1)
Proposed HPV vaccination recommendations (2015) (1)
HPV Vaccine CDC and ACIP Work Group Activities (2012) (1)
HPV vaccine availability, United States (2016) (1)
Review of data on duration of protection after HPV vaccination (2016) (1)
Changes in Cervical Cytology Results and Human Papillomavirus Types Among Persons Screened for Cervical Cancer, 2007 and 2015-2017. (2022) (1)
Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. (2022) (1)
O2-S4.03 The cost-effectiveness of human papillomavirus vaccination of females over age 12 years in the USA (2011) (1)
Cervical Intraepithelial Neoplasia Grade 3 and Adenocarcinoma In Situ: Comparison of ICD-9 Codes and Pathology Results—Kaiser Permanente, United States, 2000–2005 (2013) (1)
2-dose HPV vaccination schedule background (2016) (1)
Considerations for recommendations : ACIP HPV Vaccines Work Group (2016) (1)
Measles vaccines (2014) (1)
Very Rapid Evolution of Infection with Hepatitis C Virus Transmitted by an Accidental Needlestick (2010) (1)
Preventing vaccine-preventable diseases in low-resource communities. (2009) (1)
Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity (2016) (1)
Human papillomavirus prevalence in male and female university students in Gaborone, Botswana (2022) (1)
Maintenance of Antibody Avidity in Alaska Native Adolescents Receiving Quadrivalent Human Papillomavirus (HPV) Vaccine (2017) (1)
Evaluation of a Surveillance Case Definition for Anogenital Warts, Kaiser Permanente Northwest (2014) (1)
P1-S6.42 HPV vaccine and sexual behaviour among US adolescent and young adult women (2011) (1)
HPV Prevalence and Transmission—Reply (2007) (1)
Additional 9-valent HPV vaccination : considerations for guidance (2015) (0)
Nucleic Acid Ampliﬁcation Tests for Diagnosis of Neisseria gonorrhoeae Oropharyngeal Infections (cid:1) (2009) (0)
Twelve Years of Vaccine Registration and the Consequences (2020) (0)
Human diploid cell measles vaccine. (1985) (0)
ystematic review of human papillomavirus vaccine oadministration (2014) (0)
HPV Epidemiology, Current Status, and Challenges Associated with HPV Vaccine Uptake in the United States (2014) (0)
Improvement in healing and reduction on HIV shedding following addition of episodic Acyclovir therapy to the syndromic management of genital ulceration; a randomized controlled trial (2008) (0)
Human papillomavirus (HPV) types among Alaska native women attending a colposcopy clinic in Anchorage, Alaska, 2009–2011 (2020) (0)
Examining Self and Partners for Syphillis among MSM: Five Cities, 2009-2011 (2012) (0)
Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States. (2023) (0)
Human papillomavirus (HPV) types among Alaska native women attending a colposcopy clinic in Anchorage, Alaska, 2009–2011 (2020) (0)
Effect of Specimen Order on Chlamydia trachomatis and Neisseria gonorrhoeae Test Performance and Adequacy of Papanicolaou Smear (2006) (0)
Summary and future ACIP HPV Vaccine Workgroup plans (2014) (0)
Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact (2013) (0)
Adolescent Vaccine-Related Attitudes and Beliefs Among Key Professional Stakeholders and Opinion Leaders Across the United States (2010) (0)
Challenges to Widespread Implementation of HPV Vaccines in the USA (2007) (0)
9-valent HPV vaccine Background, transition issues and additional vaccination (2015) (0)
Genital Human Papillomavirus Prevalence Over the Lifespan Among Females and Males in a National Cross-Sectional Survey, United States, 2013–2016 (2021) (0)
Hpv prevalence and transmission. Authors' reply (2007) (0)
Multiple-type HPV infection in asymptomatic men: Prevalence and associated factors. (2006) (0)
HPV vaccination program and impact monitoring (2013) (0)
HPV Vaccination - Evolving Recommendations (2016) (0)
Human Papillomavirus Infections (2020) (0)
P3.371 Reduction in HPV Prevalence Among Young Women Following Introduction of HPV Vaccine in the United States and Estimated Vaccine Effectiveness (2013) (0)
Human Papillomavirus Vaccine and Prevention of Human Papillomavirus-Associated Disease in the USA (2013) (0)
Incidence of HSV-2 Infection Armstrong et al. Incidence of Herpes Simplex Virus Type 2 Infection in the United States (2001) (0)
Human Papillomavirus Vaccines: Considerations for Recommendations After Licensure (2006) (0)
Nucleic Acid Ampliﬁcation Tests for Diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis Rectal Infections (cid:1) (2010) (0)
The impact of the low-income housing tax credit on children's health and wellbeing in Georgia. (2018) (0)
Perfect Condom Use in a Less Than Perfect World—Reply (2006) (0)
Genital Symptoms and Genital Hsv-2 and Hiv-1 Shedding In Co-Infected Women — Chiang Rai, Thailand (2013) (0)
Response from Dr. Cleveland and colleagues. (2012) (0)
2-dose vaccination schedules bivalent and quadrivalent HPV vaccines (2016) (0)
Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27-45 years in the United States. (2023) (0)
Expanded age range for 9-valent HPV vaccine : Work Group plans and policy considerations (2018) (0)
Cervical Adenocarcinoma in Situ in the United States: Results from Population-based Laboratory Surveillance, 2008–2014 (2017) (0)
P3-S2.02 Variations in testing and treatment received by infants with possible neonatal herpes (2011) (0)
Global prevention and management of HPV related diseases : the pressing challenges and the compelling opportunities (2014) (0)
Recommendations for mid-adult HPV vaccination Work Group considerations (2019) (0)
HPV Vaccines: The Evolving Landscape (2015) (0)
Session Three: HPV Vaccination Program – Current Status and New Recommendations (2012) (0)
Sexual Mixing Patterns and Anal Human Papillomavirus Among Young Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women in 2 Cities in the United States, 2012–2014 (2020) (0)
Human Papillomavirus (HPV) Vaccines -Update (2017) (0)
88. Seroprevalence of Herpes Simplex Virus Type 1 Among Adolescents in the United States, 1999–2004 and 2005–2010 (2013) (0)
HPV AND ORAL HEALTH: Response from Dr. Cleve-land and colleagues (2012) (0)
Sexual Behavior Among US Adults: New Sex Partners and Number of Lifetime Sex Partners, NHANES 2013–2016 and NSFG 2011–2015 (2021) (0)
A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States. (2020) (0)
Postlicensure monitoring of HPV vaccination programmes. (2014) (0)
Prevalence of HPV infection among Thai schoolgirls in the north-eastern provinces in 2018: implications for HPV immunization policy (2023) (0)
P08.25 Tubal factor infertility (tfi) epidemiology in infertility clinic patients (2015) (0)
Genital human papillomavirus infection. (2006) (0)
962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016 (2019) (0)
Impact of the HPV vaccination program in the United States (2015) (0)
Systematic Review of Evidence for 2-Dose Human Papillomavirus (HPV) Vaccination Schedules (2016) (0)
The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions (2011) (0)
2-Dose HPV vaccination schedules : review of evidence (2016) (0)
1049Evaluating the Population Impact of HPV Vaccine on High Grade Cervical Intraepithelial Neoplasia Rates in an Era of Decreasing Screening (2014) (0)
Toward optimal health: a review of vaccine recommendations for women. Interview by Jodi R Godfrey. (2009) (0)
Reply to Groner et al and Pei et al. (2014) (0)
Community Intervention of Single Dose or 2-Dose Regimen of Bivalent HPV Vaccine in Schoolgirls in Thailand - Vaccine Effectiveness 2 Years after Vaccination (2022) (0)

This paper list is powered by the following services:

Lauri Ellen Markowitz's Academic­Influence.com Rankings

Lauri Ellen Markowitz's Degrees

Why Is Lauri Ellen Markowitz Influential?

Lauri Ellen Markowitz's Published Works

Published Works

Lauri Ellen Markowitz's AcademicInfluence.com Rankings